ADC Therapeutics SA 6-K, filed Nov 5, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2020.

Commission File Number: 001-39071

ADC Therapeutics SA

(Exactname of registrant as specified in its charter)

Biopôle

Route de la Corniche 3B

1066 Epalinges

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBITINDEX

Exhibit 99.1

ADCTherapeutics to Host Third Quarter 2020

FinancialResults Conference Call on November 12, 2020 **** Lausanne,Switzerland, November 5, 2020 – ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnologycompany pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patientswith hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday,November 12, 2020 at 8:30 am ET to report financial results for the third quarter ended September 30, 2020 and provide businessupdates.Toaccess the live call, please dial 833-249-8403 (domestic) or +41 225675632 (international). A live webcast of the presentation will be available under “Events and Presentations”on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available afterthe completion of the event and for 30 days following the call.AboutADC TherapeuticsADCTherapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercializationof highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. TheCompany develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD)technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs andsubstantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipelineof therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinicaltrials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and numerous preclinical ADCsin development.Loncastuximabtesirine (Lonca, formerly ADCT-402), the Company’s lead product candidate, has been evaluated in a 145-patient pivotal Phase2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overallresponse rate (ORR), which exceeded the target primary endpoint. In September 2020, ADC Therapeutics submitted a Biologics LicenseApplication to the U.S. Food and Drug Administration seeking accelerated approval for Lonca for the treatment of patients withrelapsed or refractory DLBCL. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company’s second lead product candidate,is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma(HL) after having shown in a Phase 1 clinical trial an 86.5% ORR in HL patients at the dose selected for Phase 2. The Companyis also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.ADCTherapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and NewJersey. For more information, please visit.https://adctherapeutics.com/ andfollow the Company on Twitter and LinkedIn.CONTACTS:InvestorsAmanda Hamilton ADC Therapeuticsamanda.hamilton@adctherapeutics.comTel.: +1 917 288 7023EUMediaAlexandre MüllerDynamics Groupamu@dynamicsgroup.chTel: +41 (0) 43 268 3231USAMedia Annie Starr6 Degreesastarr@6degreespr.comTel.: +1 973-415-8838